Experts from Taierkang Bio, Raynovent, Youcare Pharma, Minwei Bio and Others to Convene in Guangzhou This November with Cutting-Edge Insights

Innovation Breakthrough, Chasing the International Dream - Building a Leading Chinese World-Class Pharmaceutical Enterprise

Sino Biopharm, Executive Director, Senior Vice President

Topic Confirmation in Progress

Hui Zhengqi Pharmaceuticals, Founder

Topic Confirmation in Progress

Shanghai Global Health Innovation Research Institute, President

Tea Break

From the Investor's Perspective: The Golden Track of New Drug R&D in the Next Five Years (Proposed)

Director General, BeOne Medicines Guangzhou Innovation Center

Topic Confirmation in Progress

Guest Itinerary Confirmation in Progress

Difficulties and Future Path of Commercialization for Innovative Drug Companies

Nanjing Zhenshi, General Manager of Biology

Roundtable: NewCo and BD Overseas for ADC Drugs

Cao Fei InxMed, Co-Founder/Chief Operating Officer

Fang Xianfeng Beijing Senmiao Bio, CEO

Huang Xianming Bio-Thera, Vice General Manager

Hua Jiang BeOne Medicines, Executive Director of External Innovation and Cooperation

Li DahuFosun Pharma, Co-General Manager of Strategic Investment Department

Lunch

Development of Antibody-Drug Conjugates (ADC)/Radionuclide-Drug Conjugates (RDC) for Novel Anti-Cancer Drugs

NanAn Bio, Chairman & Chief Scientist

XDC Era: AI-Powered Integrated Design of Antibody-Peptide-Small Molecule

Viva Biotech, Vice President of Shanghai Bio & Head of Large Molecule Drug Development Platform

Subject to be determined

Dongyang Guang Medicine, Director

Key Influencing Factors in Antibody Design for ADCs

JOINN, Manager

Topic Confirmation in Progress

Viva Biotech, Founder, President, and Co-Chief Medical Officer

Data-Driven Drug Development

Guest Itinerary Confirmation in Progress

ADC Drug Development Case Studies (Proposed)

Medicilon, Head of ADC Platform

Topic Confirmation in Progress

Head of Pfizer Oncology Pipeline and Project Management

Development Potential of China-Produced ADC Drugs from the FDA's Perspective

Senior Vice President and Global CBO of Evergreen Therapeutics

FDA Expert Interpretation: How to Efficiently Advance Global Clinical Trials

Evergreen Therapeutics, Chairman, Founder

Multicenter Clinical Trial Monitoring Coordination Strategy

Haichang Bio, Founder

The Art of Global Compliance and Regulatory Communication for Products

Representative of the U.S. PATH China Office / Former Chief Reviewer and Inspector of the U.S. FDA Center for Biologics Evaluation and Research

Subject Confirmation

Norse BioPharma, Chief Scientific Officer

Trends in Peptide and GLP-1 Drug Development (Draft)

Professor at the Center for Drug Metabolism Research, China Pharmaceutical University

PDC Peptide-Drug Conjugates: Expansion into Non-Oncology Indications (Proposed)

Taierkang Bio, Founder

Multi-Target Targeted Delivery Peptides and Multi-Target Targeted Peptide Drug Discovery and Development

Shenzhen Peptide Prosperity Biotech, Chairman

Tea Break

Topic Confirmation in Progress

Guest Itinerary Confirmation in Progress

How to Break Through the GLP-1 Product Involution (Proposed)

Zhongsheng Ruichuang, Co-Founder, Director, President

AI-Based Original Antiviral Peptide Development

Yuekang Pharmaceuticals, President of the Research Institute, Vice General Manager

Topic Confirmation in Progress

Gloria Biosciences (Hangzhou) Co., Ltd., Founder, Chairman and CEO

Lunch

Progress of PDC Drug MB0151 Targeting SSTR-2

Mainstream Source Biotechnology Co., Ltd., Non-Clinical Director

Design and Development of Novel Peptide-Conjugated Drugs (Proposed)

Hanking Pharmaceuticals, CEO

Regulatory Requirements for the Development and Marketing of Peptide Drugs

Evergreen Therapeutics, General Manager

Application of Bifunctional Peptides in Renal Metabolism and Cardiovascular Therapeutics

McAllister, CFO

Quality Research and Control Strategy for Peptide Active Pharmaceutical Ingredients

Pro Pharma, Chief Technology Officer of Peptides

Tea Break

Differentiated Layout Ideas for GLP-1 Class Products

People as Biological, BD Director

Regulatory Requirements and Differences for Clinical Trials in Different Regions

Evergreen Therapeutics, Co-Founder & CMO

Research and Development of Bone Regeneration Targeting Peptide Drugs (Proposed)

Leiborichen, Senior Director

Discovery and Translation of Novel Long-Acting Peptide Drugs for Hypoglycemic and Weight Loss Based on PTPN1/2 Inhibitors/Degraders

Associate Professor, Department of Medicinal Chemistry, College of Chemical Engineering, Qingdao University of Science and Technology

Screening of Drug Targets for Metabolic Diseases

Professor, School of Life Sciences, Fudan University, Doctoral Supervisor

Development of Innovative Cyclic Peptide Drugs

Xianggen Bio, Co-Founder/Chief Scientist

Efficient Discovery and Creation of Small FIC Molecules from Marine Microorganisms

Professor, School of Pharmaceutical Sciences, Wuhan University

Application and Case Sharing of DEL+AI in Early Drug Discovery

Director/Project Director of Green Synthesis R&D Center, Innovation Center for Small Molecule New Drugs, Guangdong Province

Coffee Break

How AI Workstations Accelerate the Process and Drugability Evaluation of Innovative Drugs

Guest Itinerary Confirmation in Progress

How Artificial Intelligence Advances Clinical Research

Professor, Xiangya School of Pharmaceutical Sciences, Central South University

Roundtable: Key Points and Logic of Technology Transfer

Chen JunsongAssociate Professor, Institute of Systems Biomedicine, Shanghai Jiao Tong University (Host)
Tan FenlaiLupeng Pharma, Founder and CEO

Hua JiangBeOne Medicines, Executive Director of External Innovation and Cooperation

Zheng HongshuPierre Fabre, Senior Director of Market Access for the Asia-Pacific Region, Senior Director of Business Development in China

Tang JiansongDirector of Investment, Guangdong Technology Venture Capital

Zhang YingXtalPi, Head of Business Development

Differentiated Small Molecule Innovative Drug Project Selection

Force Life Sciences, CO-CEO & CSO

Discovery of a Novel Allosteric Inhibitor of TYK2

Sino Biopharm, Senior Director

Preclinical and Clinical Research on Original New Target DRIP Inhibitor for Cancer Prevention and Treatment

Professor at the Hong Kong University of Science and Technology, Chief Scientific Officer and Chairman of Encheng Pharmaceuticals

Topic Confirmation in Progress

Jacobio Pharmaceuticals, VP of Medicinal Chemistry

Clinical Development and Commercialization of Lobutinib, a Novel Class I Drug

Lupeng Pharmaceuticals, Founder and CEO

Research and Translation of Novel Kinase Inhibitors to Overcome Clinical Drug Resistance in Tumors

Professor, Doctoral Supervisor, Vice Dean of the School of Pharmacy, Jinan University

Organoids + AI Empower the Development of the First Targeted Drug for Diffuse Gastric Cancer

Signet Biotech, Founder and CEO

Roundtable: Global Collaboration Trends of China's Innovative Pharmaceutical Companies

Yang WenxianEuphorbia, Vice President, Dean of the Research Institute

Lunch

Development and Global Collaboration of Small Molecule Innovative Drugs

Senior Director of Product Line Management and External Cooperation at Jiayue Pharmaceuticals

Development Prospects of Small-Molecule Anticancer Conjugate Drugs

Aixindawei, Chairman and General Manager

Advances in Clinical Research on Small Molecule Inhibitors Targeting RNA Helicases

Kaiyue Life, Chairman and Chief Scientist

Innovative Molecules for Stroke (Proposed)

Guangzhou Sci-Tech Pharm, General Manager

Pain Drug Development

Calithera Biosciences, Co-founder and CEO

In-situ Neural Regeneration Technology in the Brain and Clinical Translation

Shenxi Bio, Founder & Chief Scientist & Chairman; Director of the Brain Repair Center at Jinan University

Topic Confirmation in Progress

Guest Itinerary Confirmation in Progress

Lifecycle Management of Process Validation

CR Biopharm, Chief Manufacturing Officer

Application of Innovative Drug Solid Dispersion Formulation Development in Preclinical and Clinical Research (Proposed)

Anrui Biotech, Vice President/CMC Head

ADC New Drug Regulations and Registration

Evergreen Therapeutics, Founder & CEO

Tea Break

Industrial Development Examples of ADC Drugs

Sino Biopharm Nanjing Shunxin Pharmaceutical, Production Manager

Case Study on the Development of Small Molecule New Drug Processes

Hibiscus Chemistry, CEO

CMC Development of ADC Biosimilars

Guest Itinerary Confirmation in Progress

Lunch

Case Study on Peptide Drug Impurity Control and Process Changes (Proposed)

General Manager of the Polypeptide Division / Deputy General Manager of the Group / Deputy Dean of the Research Institute, Jiangsu Notch Biotechnology Co., Ltd.

Innovative Strategies and Case Analysis for Peptide Drug Formulations

Shankang Pharmaceuticals, Chief Technology Officer

Research Progress on Long-Acting Peptide Formulations

Head of Formulations, Beijing Research Institute, CSPC Group

Early Process Development and FIH Formulation Study of PROTAC Drugs

Gan & Lee Pharmaceuticals, Executive Director of Chemical Process Department

Process Development of Recombinant GLP-1 Drugs Based on QbD

Senior Manager of Federal Biologics, Microbial Process Development Platform & Hengqin Early Development Platform

GLP-1 Process Development and Breakthrough in Long-Acting Delivery Technology

Guest Itinerary Confirmation in Progress